A ortic aneurysms, including thoracic aortic aneurysm (TAA) and abdominal aortic aneurysm (AAA), are life-threatening cardiovascular events that are characterized by a permanent dilatation of the aorta and have an extremely high mortality rate on rupture. TAA and AAA differ in anatomic location of aortic dilatation, risk factors, genetic polymorphisms, and histological characters.
another and differ in embryology of vascular smooth muscle cells (VSMCs) origin. 10 The latter has been suggested to possibly contribute to the different pathogenesis of TAA and AAA. 2 Although recognized as distinct disease entities, both TAA and AAA are pathologically characterized by vascular extracellular matrix destruction/remodeling and a loss of VSMC contractile function. 11, 12 Although not fully understood, VSMCs are highly phenotypically plastic, and the loss of the contractile phenotype of VSMCs has been recognized as an early event in both thoracic and AAAs in a variety of animal models and human aneurysmal tissues. 13, 14 However, the molecular linker connecting VSMC phenotypic transition and aortic aneurysm remains elusive. XBP1 (X-box binding protein 1) is a key transcription factor controlling the endoplasmic reticular (ER) stress response and is crucial for cell survival under stress conditions. 15, 16 There are 3 pathways in the ER-stress response: the PERK (protein kinase R-like ER kinase), ATF-6 (activating transcription factor 6), and IRE1α (inositol-requiring enzyme 1 α) pathways. On sensing the accumulation of unfolded proteins, IRE1α cleaves unspliced XBP1 (XBP1u) mRNA and removes a 26-nucleotide-long intron, resulting in the production of a spliced XBP1 (XBP1s). 17 XBP1u and XBP1s have an identical N-terminal dimerization domain and internal DNA-binding domain but differ in their C termini. 17 XBP1s then translocates to the nucleus and transcriptionally regulates genes that are involved in protein folding, glycosylation, ER-associated degradation, autophagy, lipid biogenesis, and insulin secretion, among others. 16, 18, 19 Compelling evidence has suggested an essential role of XBP1 splicing in angiogenesis, 20 endothelial proliferation, and apoptosis 20, 21 and in VSMCs migration 22 during the disease states of atherosclerosis and postinjury neointima formation. However, little is known about the physiological function of XBP1u. Previous studies have indicated that XBP1u counteracts XBP1s by shuttling between the nucleus and the cytoplasm and sequestering XBP1s for proteasomal degradation. 23 A recent study has revealed a role for XBP1u in controlling autophagy by recruiting FoxO1 (Forkhead box protein O 1) to the 20S proteasome. 24 Intriguingly, global knockout of XBP1 causes embryonic lethality at embryonic day (E) 13.5 and leads to reduced vessel formation, thus indicating a pivotal role for XBP1 in vascular differentiation/development and function. 20 Previous research has indicated that XBP1u protects endothelial cells from disturbed flow-induced oxidative stress through interaction with histone deacetylase 3 in the cytosol. 25 In the current study, we sought to clarify whether XBP1u is also involved in VSMC homeostasis and, therefore, modulates aortic aneurysm formation.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Angiotensin II-Induced Aortic Aneurysm in Apolipoprotein E Double Knockout Mice
Sixteen-week-old XBP1
WT apolipoprotein E knockout (ApoE −/− ) and XBP1
SMKO

ApoE
−/− male mice were infused with angiotensin II (AngII; 1000 ng/kg per minute; Sigma Aldrich, Inc) via subcutaneous osmotic minipumps (Model 2004; ALZA Scientific Products) as described previously. 26, 27 Systolic blood pressure was measured before and after AngII infusion in conscious mice using the noninvasive tail-cuff BP-2000 system (Visitech Systems, Inc, NC). Aortic diameters were obtained by in vivo measurements using the Vevo 770 ultrasound system (Visualsonics, Toronto, Canada). In addition to in vivo measurements, aortas from saline-or AngII-infused mice were 
Novelty and Significance
What Is Known?
• The phenotypic switch of vascular smooth muscle cells (VSMCs) precedes aortic aneurysms.
• XBP1 (X-box binding protein 1), which exists in a transcriptionally inactive unspliced form (XBP1u) and a spliced active form (XBP1s), is a key factor controlling the endoplasmic reticular stress response.
What New Information Does This Article Contribute?
• XBP1u is essential for maintaining VSMC homeostasis via an endoplasmic reticular stress-independent effect. • XBP1u deficiency in VSMCs causes both thoracic and abdominal aortic aneurysms in mice.
• The XBP1u-FoxO4 (Forkhead box protein O 4)-myocardin axis in smooth muscle cells plays a pivotal role in maintaining the VSMC phenotype and preventing aortic aneurysm formation.
The molecular link connecting VSMC phenotypic switching and aortic aneurysm development remains elusive. Our study revealed that XBP1u is pivotal for maintaining the contractile phenotype of VSMCs and prevents aortic aneurysm formation. Mechanistically, XBP1u directly binds to cytoplasmic FoxO4 and prevents FoxO4 nuclear translocation and subsequent repression of myocardin-mediated contractile apparatus transcription in VSMCs. Interrupting the XBP1u-FoxO4 interaction promotes the proinflammatory and proteolytic phenotype of VSMCs in vitro and stimulates aortic aneurysm formation in vivo. Our study highlights the importance of XBP1u-FoxO4-myocardin interactions in modulating VSMC phenotypic transition during aortic aneurysm formation.
dissected after euthanasia and perfusion with 4% paraformaldehyde to measure the aortic diameters ex vivo. Aortic aneurysm in this model is mainly localized to the suprarenal abdominal aorta (distal to the renal arteries), followed by the thoracic aorta (ascending aorta and descending aorta), and defined as a localized dilation of aorta >50% of its adjacent intact portion of aorta. 28, 29 Pathological insights include elastin fragmentation, inflammatory cells infiltration particularly in the adventitia, and plasma inflammatory cytokines increase.
11,12
Luciferase Reporter Assays HEK293A, COS-7 cells, or human VSMCs (T/G HA VSMC) were transiently cotransfected with luciferase reporter and β-galactosidase plasmids using Jet-PEI reagent according to the manufacturer's protocol. One day later, transfected cells were harvested for luciferase activity measurement using a luciferase assay kit (Promega, Madison, WI) and β-galactosidase activity detection using the OPNG (orthonitrophenyl-β-galactoside) reaction (Promega). The transcriptional activity was presented as the ratio of luciferase activity to respective β-galactosidase activity.
Recombinant Adenovirus Construction and Infection in Mice
A murine FoxO4 amino acid (aa) 1 to 89 dominant-negative fragment (FoxO4-DN) was subcloned into an adenovirus vector pDC316-mCMV-EGFP. Subsequently, the recombinant adenovirus plasmids pDC316-mCMV-FoxO4-DN-EGFP were cotransfected with pAV. Des1d vector into HEK293A cells to yield the final expression clone Ad-FoxO4-EGFP. Ad-FoxO4-EGFP was amplified by infecting HEK293A cells and purified by PD-10 Sephadex precipitation. An adenovirus vector carrying green fluorescence protein (Ad-EGFP) was applied as negative control. For in vivo studies, 1×10 9 plaqueforming unit of adenovirus dissolved in 30% pluronic gel solution were perivascularly delivered to the suprarenal aortas as described previously. 30 The EGFP fluorescence signal was monitored by confocal laser scanning microscopy to demonstrate the infection of adenovirus to the medians of the aortas.
Statistical Analysis
All data are expressed as the mean±SEM. Statistical analysis was performed using GraphPad prism 6.0 software (GraphPad Software, San Diego, CA). For statistical comparisons, whether data were normally distributed was first evaluated. Then, a check was made for similar variances among normally distributed data, followed by Student t test for 2-group comparisons and ANOVA for comparisons if evaluations of similar variances were passed. Nonparametric tests were used where data were not normally distributed. In all cases, statistical significance was concluded where the 2-tailed probability was <0.05. Table I) . 12, 26, 31 Therefore, we first compared the aortic expression levels of spliced and unspliced XBP1 and contractile apparatus proteins at early stages (3 and 7 days) in AngII-infused ApoE −/− mice. As expected, VSMC-specific smooth muscle α-actin (SMA), calponin, and SM22α (smooth muscle 22 α) were significantly decreased as early as 3 days post-infusion; the reduction persisted through 7 days ( Figure 1A ). Intriguingly, the protein level of XBP1u but not XBP1s was similarly reduced with the contractile proteins in both thoracic (including ascending and descending aortas) and abdominal aortas ( Figure 1A ). To further confirm these observations, we used another CaPO 4 -(calcium phosphate) induced AAA model in C57BL/6J mice (Online Figure ID and IE) . Similarly, XBP1u but not XBP1s was repressed in the abdominal aorta during different stages of aneurysm formation (3, 5, and 7 days), which is consistent with VSMC dedifferentiation (Online Figure IF) . Immunohistochemical analysis further confirmed great reductions of XBP1u and VSMC-specific SM22α in the medium tunica of both thoracic (including ascending and descending aortas) and abdominal aortic aneurysmal vessel wall in 7-day consecutively AngII-infused ApoE −/− mice ( Figure 1B ), whereas no positive staining was detected by the species-matched IgG (data not shown). To determine the cellular localization of XBP1u, confocal fluorescence microscopy was performed on normal aortic tissue. XBP1u colocalized primarily in the medial SMCs ( Figure 1C ). Of interest, 10% fetal bovine serum, which causes VSMCs dedifferentiation, significantly inhibited, whereas TGF-β (5 ng/mL) stimulation, which causes VSMCs differentiation, greatly upregulated, XBP1u expression in VSMCs (Online Figure IG) . Taken together, XBP1u reduction may be involved in the phenotypic transition of VSMCs during the pathogenesis of aortic aneurysm.
In addition, to assess whether ER-stress response is activated at early stage of aortic aneurysms formation, the expression of ER-stress molecules including GRP-78, ATF-6, p-eIF2α, and XBP1s was detected by Western blot (Online Figure IF , IH, and II; Figure 1A ). Consistent with previous studies, 32, 33 GRP-78 and p-eIF2α were increased and total ATF-6 was reduced in both AngII-and CaPO 4 -induced aneurysmal mice (Online Figure IH and II). In contrast, XBP1s was not altered, whereas XBP1u was repressed at early stage of aneurysmal aortas ( Figure 1A ; Online Figure IF ). Therefore, XBP1u reduction but not XBP1s-mediated ER stress at early stage may be involved in aneurysm formation. To ask why XBP1u was repressed during aortic aneurysms development, we further evaluated the regulatory mechanism of XBP1u. First, real-time polymerase chain reaction results indicated that XBP1u mRNA was significantly decreased in AngII-infused thoracic and abdominal aortas (Online Figure  IIA) . Similarly, both XBP1u mRNA and protein levels were greatly downregulated in response to AngII in vitro (Online Figure IIB and IIC) . Next, we found that AngII did not transcriptionally affect XBP1u, whereas ATF6 34 did as evidenced by luciferase reporter assay (Online Figure IID) . Next, we applied actinomycin D to test whether XBP1u was posttranscriptionally regulated by inhibition de novo synthesis of mRNA in VSMCs. Intriguingly, the half-life of XBP1u mRNA was markedly reduced in response to AngII (t 1/2 from 90.3 to 51.9 minutes; Online Figure IIE ), indicating that AngII may regulate XBP1u expression via destabilizing mRNA. Moreover, we applied cycloheximide and MG-132 to inhibit de novo protein synthesis and proteasomal degradation, respectively. As shown in Online Figure IIF 
XBP1 Deficiency in VSMCs Causes Smooth Muscle Cell Dedifferentiation and Aggravates Aortic Aneurysms In Vivo
Next, we investigated whether XBP1u reduction causes VSMC phenotypic transition and aortic aneurysm. At 4 months of age, the contractile apparatus proteins were greatly reduced in both thoracic (including ascending and descending aortas) and abdominal aortas in SM22-Cre WT mice were treated ex vivo in the absence or presence of AngII (1 μmol/L). The secretion of the proinflammatory cytokines MCP-1 and IL-6 and the protease activity of MMP-2 and MMP-9, which have been repeatedly demonstrated to contribute to the pathogenesis of aortic aneurysm, 35, 36 were significantly elevated in the conditioned media from XBP1 SMKO aortic rings compared with XBP1
WT aortic rings (Online Figure  IIID and IIIE) , suggesting that XBP1 deficiency may facilitate VSMC transition toward an inflammatory and proteolytic phenotype. Thus, the effect of XBP1 deficiency in the development of aortic aneurysm was determined by crossing VSMC conditional XBP1
SMKO with hyperlipidemic ApoE −/− mice. After AngII (1000 ng/kg per minute) infusion for 4 weeks, systolic blood pressure increased similarly in XBP1
SMKO
ApoE
−/− and XBP1
WT
ApoE
−/− mice, but no obvious difference was observed in body weight, plasma lipids, or survival rates between the groups of mice (Online Table II ; Online Figure IVA ). These data suggest that the effects of SMC-derived XBP1 deficiency were independent on arterial hypertension elevated by AngII or plasma lipids. In the absence of AngII infusion, no mice developed spontaneous aortic dilations and aneurysms (Figure 2A though 2E) . Nevertheless, in the presence of AngII, XBP1
SMKO
ApoE
−/− mice exhibited a significant increase in maximal aortic diameter compared with XBP1 WT ApoE −/− mice in the thoracic aortas (aortic root, ascending, and descending) by both ultrasound and ex vivo measurements (Online Figure IVB; Figure 2B ). Similarly, XBP1 deficiency in VSMCs enhanced the AAA formation, and the incidence of AAA at 28 days was markedly increased, from 55.55% in AngII-infused XBP1 Figure  IVD) . In parallel, the upregulated proinflammatory cytokines MCP-1 and IL-6 were observed in plasma (Online Figure  IVE) . Consistently, the aortas from XBP1
SMKO
ApoE
−/− mice infused with AngII displayed a marked upregulation of MMP-2 and MMP-9 protein expression in both thoracic and abdominal aortas (Online Figure IVF) . Meanwhile, no positive staining was detected by the species-matched IgG (data not shown). To further verify the role of XBP1 deletion in the pathogenesis of aortic aneurysm, we used a CaPO 4 -induced AAA model in XBP1
SMKO and XBP1 WT mice. Consistent with the previous results, VSMC-specific XBP1 deficiency facilitated CaPO 4 -induced AAA formation (Online Figure IVG and IVH) . Taken together, XBP1 deficiency in VSMCs causes VSMC dedifferentiation toward a proinflammatory phenotype and aggravates aortic aneurysms in vivo.
Unspliced XBP1 Maintains the Contractile Phenotype of VSMCs
To explore the definitive alteration of VSMCs because of XBP1 deficiency, we isolated primary VSMCs from XBP1 SMKO and XBP1
WT mice. As shown in Figure 3A , the expression of SMA, calponin, and SM22α were significantly decreased in XBP1-deficient VSMCs from both thoracic and abdominal aortas. Further siRNA knockdown of XBP1 in serum-starved differentiated VSMCs resulted in morphological changes from a spindle-like contractile phenotype to a polygonal synthetic phenotype (Online Figure VA and switching, siRNA targeting IRE1α and the specific IRE1α endoribonuclease inhibitor salicylaldehyde 37 were used to inhibit XBP1 splicing (Online Figure VC) . Interestingly, IRE1α silencing or salicylaldehyde application in serum-starved VSMCs displayed no effect on VSMC dedifferentiation, indicating XBP1u, rather than XBP1s, may contribute to maintaining the contractile phenotype of VSMCs (Online Figure  VD ; Figure 3B ). Similar results were observed in primary cultured rat VSMCs (Online Figure VE) . Moreover, on AngII (1 μmol/L) stimulation, XBP1 silencing greatly induced the expression or secretion of proinflammatory cytokines MCP-1, IL-6, TNF-α, and IL-1β (Online Figure VF , VG, and VI), upregulated MMP-2 and MMP-9 mRNA expression (Online Figure VH and VI) , and enhanced metalloproteinase activity (Online Figure VJ) in both aortic smooth muscle cell line and primary cultured VSMC, as well as facilitated increased macrophage recruitment toward VSMCs (Online Figure VK) . In contrast, inhibiting XBP1 splicing did not affect the above changes (Online Figure VF through VK) . Accordingly, overexpression of XBP1u but not XBP1s in primary VSMCs with XBP1 
Unspliced XBP1 Modulates VSMC Phenotype via FoxO4
To address the underlying mechanism by which XBP1u regulates VSMC contractile proteins expression, we first investigated whether XBP1u directly upregulated SMC contractile proteins transcription with a luciferase reporter assay ( Figure 4A ). Transfection of myocardin, a potent transcriptional activator of SMC marker genes, into COS-7 cells induced a significant increase in expression of luciferase reporters controlled by the promoters of SMA and SM22α. In contrast, transfection of XBP1u or XBP1s alone did not affect the luciferase reporter activity (Figure 4A ), suggesting that XBP1u does not directly regulate SMC markers at the transcriptional level. Second, we hypothesized that XBP1u may affect SRF (serum response factor), a master transcriptional factor for SMC contractile marker genes, by binding to the CArG box of SMC marker gene promoters. 38 As shown by the ChIP (chromatin immunoprecipitation) assay in Figure 4B , silencing XBP1 did not affect the binding activity of SRF to the CArG box of SMA and calponin gene promoters. Moreover, the expression levels of a well-recognized transcriptional factor (SRF), coactivators (myocardin and MRTF [myocardin-related transcription factor]) 39, 40 or suppressors (KLF4 [Krüppel-like factor 4] and FoxOs) 41, 42 of VSMC markers were not altered at both the mRNA and protein levels (Online Figure VIA and VIB) . Next, we investigated whether XBP1 modulates the subcellular translocation of SMC transcriptional cofactors, as compelling evidence indicate that cytoplasmnuclear redistribution of SMC cofactors greatly affects the transcriptional program for SMC differentiation. For example, PI3K/Akt signaling promotes SMC differentiation, at least in part, by stimulating nuclear export of FoxO4, thereby releasing myocardin from its inhibitory influence. 41 As shown in immunofluorescence assays, the silencing of XBP1 but not IREα in serum-starved contractile VSMCs accelerated the nuclear translocation of FoxO4 ( Figure 4C ). In contrast, XBP1 and IREα silencing did not affect the subcellular redistribution of myocardin ( Figure 4C ), which is consistent with constitutive nuclear localization of myocardin. 40 Concomitantly, ectopic overexpression of XBP1u, but not XBP1s, in serum-rich dedifferentiated VSMCs and primary cultured rat VSMCs facilitated FoxO4 shuttling from the nucleus to the cytoplasm in conjunction with morphological alteration of VSMCs from the synthetic to the contractile phenotype (Online Figure VIC and VID). Both in vitro and in vivo analysis further revealed colocalization of XBP1u and FoxO4 in the cytoplasm of both primary VSMCs and aortic walls from thoracic and abdominal aortas in XBP1 WT mice, whereas there was a nuclear localization of FoxO4 in XBP1 SMKO mice (Online Figure VIE and VIF). To further assess whether XBP1u modulates VSMC differentiation by interfering with FoxO4, we performed a luciferase reporter assay. In accordance with previous reports, FoxO4 represses myocardin-induced transactivation of CArGdependent SMA-luciferase (luc) and SM22α-luc ( Figure 4D ). This effect could be effectively circumvented by XBP1u but not XBP1s (Figure 4D ), suggesting that XBP1u may counteract FoxO4 activity. Accordingly, XBP1 silencing-induced VSMC dedifferentiation was abolished by additional FoxO4 knockdown (Online Figure VIG and VIH) , thus reinforcing the idea that XBP1u maintains the contractile phenotype of VSMCs by negatively regulating VSMC marker repressor FoxO4.
Unspliced XBP1 Directly Interacts With FoxO4
Next, we investigated whether XBP1u directly interacts with FoxO4 and therefore affects its subcellular localization. On serum stimulation, FoxO4 was mostly retained in the nucleus, whereas XBP1u was most abundantly expressed in the cytoplasm ( Figure 5A ). With serum starvation, FoxO4 was enriched in the cytoplasm and colocalized with XBP1u ( Figure 5A ). Next, we tested whether endogenous XBP1u interacts with myocardin and FoxO4 by coimmunoprecipitation assays in differentiated VSMCs. As shown in Figure 5B , XBP1u specifically coimmunoprecipitated FoxO4 in differentiated VSMCs and vice versa. In contrast, there was no direct interaction between XBP1u and myocardin, neither between XBP1u and FoxO4 in dedifferentiated SMCs (Online Figure VIIA and VIIB). Meanwhile, we confirmed the interaction of XBP1u and FoxO4 in primary aortic SMCs isolated from XBP1 WT mice but not in XBP1 deficiency SMCs (Online Figure VIIC) . Because XBP1u and XBP1s share the same N-terminal domain, we then tested whether spliced XBP1 interacts with FoxO4 in SMCs. Interestingly, the interaction of XBP1s with FoxO4 was not observed in differentiated SMCs ( Figure 5C ). Furthermore, a direct interaction was further confirmed by cotransfection of HEK293A cells with His-FoxO4 and Flag-XBP1u plasmids before coimmunoprecipitation. The anti-Flag antibody specifically immunoprecipitated His-tagged FoxO4 with XBP1u, whereas control IgG did not ( Figure 5D ), suggesting a direct association between XBP1u and FoxO4. Next, we tried to map the precise binding domain between XBP1u and FoxO4 by pull-down assays. GST (glutathione S-transferase)-fused full-length, N-terminal (aa 1-101) and C-terminal (aa 89-261) constructs of XBP1u were incubated with purified MBP (maltose-binding protein)-FoxO4 protein in vitro. As shown in Figure 5E , both the full-length and N-terminal XBP1u constructs efficiently immuno-interacted with FoxO4, whereas the C-terminal XBP1u construct did not bind. In addition, we performed MBP pull-down assays to determine the binding domain of FoxO4 with XBP1u. As shown in Figure 5F , the full length and N terminus of FoxO4 (aa 1-89), but not other domains, were required for the interaction with XBP1u. Together, our data provide the direct evidence that XBP1u directly associates with FoxO4 in contractile SMCs. 
XBP1u-FoxO4 Cytoplasmic Association Prevents FoxO4 Nuclear Translocation and Myocardin Repression in VSMCs
As FoxO4 negatively regulates myocardin activity and represses SMC contractile marker genes transcription, 41 we hypothesized that an association between XBP1u and FoxO4 may interfere with the FoxO4-myocardin interaction and the subsequent release of myocardin coactivator activity. To address this issue, we performed coimmunoprecipitation assays in HEK293A cells transfected with Flag-myocardin and His-FoxO4 in the presence or absence of XBP1u or XBP1s ( Figure 6A ). Indeed, XBP1u but not XBP1s inhibited the interaction between FoxO4 and myocardin ( Figure 6A) . Furthermore, the N terminus of FoxO4 (aa 1-89) was used as a dominant-negative control (FoxO4-DN) to block the interaction between FoxO4 and XBP1u (Online Figure VIIIA) . As a consequence, FoxO4 was translocated to the nucleus of differentiated VSMCs, the interaction between FoxO4 and myocardin increased, and the SMC marker genes were markedly repressed at both the mRNA and protein levels (Online Figure VIIIB and VIIIC; Figure 6B and 6C). In parallel, the proinflammatory cytokine and MMP expression levels were significantly upregulated, even in the absence of stimulus ( Figure 6D ). To reinforce the observation in vivo, an adenovirus flanking the dominant-negative domain (Ad-FoxO4-DN, 1×10 9 plaque-forming unit per mouse) was periadventitially applied to the ApoE −/− mice at the suprarenal abdominal aorta (Online Figure VIIID) , and these mice were then exposed to AngII infusion for 4 weeks. As shown in Figure 6E and 6F, Ad-FoxO4-DN-infected mice had pronouncedly aggravated AngII-induced AAA (Ad-FoxO4-DN+AngII, 50%, n=8, versus Ad-EGFP+AngII, 100%, n=8, P=0.021) in vivo without influencing the body weight, blood pressure, or survival rate of mice (Online Table III 
Discussion
The role of VSMC homeostasis during aortic aneurysm remains elusive. Herein, we have identified an essential role of XBP1u in maintaining the VSMC contractile phenotype and suppression of vascular inflammation and proteolytic degradation in vitro and in vivo. Intriguingly, our study revealed an XBP1u-FoxO4-myocardin network that regulates the VSMC phenotypic transition and vascular homeostasis, which may reflect some commonality in the pathophysiology of both AAA and TAA.
In the current study, we identified unspliced XBP1 as a molecular link between VSMC homeostasis and aortic aneurysm formation. Vascular SMCs are highly plastic and susceptible to phenotypic switching from a contractile phenotype toward a synthetic, inflammatory, or even osteochondrogenic phenotype on various stimulations. 13, 22, 30, 43 The dedifferentiation of VSMCs has been repeatedly observed during the early onset of a variety of vascular diseases, including Marfan syndrome, AAA, and dissection. 13, [44] [45] [46] Dedifferentiated VSMCs are prone to migration, 22, 47 produce more inflammatory cytokines, 48 exhibit greater proteolytic activity 13, 48 than contractile VSMCs, and subsequently contribute to vascular remodeling. Thus, it is pivotal to uncover the endogenous molecules that maintain the contractile phenotype and homeostasis of VSMCs. Previous studies identified contractile proteins (SMA and smooth muscle MYC11), 5, 6 membrane receptor (TGF-β receptor II), 46 transcriptional factor or coactivator (SRF and myocardin), 38, 39 signaling molecules (integrin ILK and AKT), 49, 50 and ECM (extracellular matrix) protein (fibrillin-1) 4,51 that maintain VSMC homeostasis and resist aortic aneurysm and dilation. Herein, we revealed that XBP1u-deficient VSMCs lost the contractile phenotype and were susceptible to both AngII-induced TAA and AAA and CaPO 4 -induced AAA. XBP1-deficient or silenced VSMCs expressed fewer contractile proteins, higher MMP-2/MMP-9 expression and activity, and increased inflammatory cytokines. These observations are in accordance with previous reports of MMP-2/9 36 and MCP-1/IL-6/IL-1 35, 52 functioning in aortic aneurysm. Moreover, the observation of an essential role of XBP1u in maintaining the VSMC differentiated state is also consistent with a report that XBP-1 global knockout mice exhibit embryonic lethality at E13.5 with reduced vessel formation. 20 Notably, our study excludes the dependence of XBP1 splicing-linked ER stress with regard to unspliced XBP1 for maintaining VSMC homeostasis and prevention of aortic aneurysm. In general, the accumulation and aggregation of misfolded proteins and sustained ER-stress responses are common features of cardiovascular disorders. Previous studies have reported that ER-stress molecules including GRP-78, GRP-94, p-eIF2α, ATF6α, and XBP1s were elevated in aneurysmal areas of human AAA and AngII-induced ApoE −/− mice. 33 A deficiency of CHOP, (C/EBP homologous protein) a mediator of ER stress in mice, prevents TAA/thoracic aortic dissection. 53 However, these markers were detected mostly at late stage of aneurysmal aorta, and there is lack of direct evidence on which ER-stress signaling pathways participate in the pathogenesis of aortic aneurysms. In the current study, we observed no obvious alteration of XBP1s at the early stages of 2 different murine models of aortic aneurysm ( Figure 1A ; Online Figure  IF) , which may be because of p-eIF2α-mediated inhibition of translation. 54 In contrast, XBP1u was markedly decreased with time, in parallel with the repression of the smooth muscle contractile apparatus proteins (Figure 1A and 1B; Online Figure IF) . Silencing of XBP1, but not an inhibition of XBP1 splicing or IRE1α, facilitates VSMC phenotypic switching toward synthetic and inflammatory phenotypes, showing that XBP1u protection of VSMCs overwhelmed XBP1s during the pathogenesis of aortic aneurysm. Of interest, VSMC dedifferentiation is also a hallmark of postinjury restenosis in vessels, and a previous study using the same SMC-specific XBP1 knockout mice has shown that XBP1 deficiency in VSMCs abrogates neointimal lesions of injured vessels. 22 This discrepancy may be because of different injuries in different animal models. Indeed, the latter has reported that PDGF-BB (platelet-derived growth factor-BB) activated XBP-1 splicing via interaction with the PDGF receptor, and, therefore, XBP1s increased SMC migration and contributed to neointima formation, 22 suggesting a context-dependent role for XBP1u and XBP1s in various vascular disease states.
Another interesting finding of the current study is the novel network of XBP1u-FoxO4-myocardin in maintaining VSMC homeostasis ( Figure 7) . Compelling evidence has indicated that myocardin is an essential coactivator of SRF and is a master regulator of VSMC differentiation. 55 SRF binds to CArG boxes and transcriptionally activates a variety of downstream muscle-specific genes, such as SM22α, ACTA2, MYH11, and several other signaling pathways. 55 A reduction of myocardin availability for SRF by other myocardin-binding proteins, such as FoxO4, leads to decreased expression of VSMC contractile apparatus genes. 41, 55 In contrast, FoxO4 nuclear export to the cytoplasm leads to the release of myocardin and VSMC differentiation. 41 In the current study, we unraveled a novel regulatory mechanism of myocardin activity and VSMC differentiation. In brief, XBP1u binding to FoxO4 in cytoplasm inhibits FoxO4 nuclear translocation and association with myocardin in the nucleus. XBP1 deficiency led to the nuclear accumulation of FoxO4, repressed myocardin activation, reduced SMC marker gene expression, and enhanced inflammatory responses in the vessels. Disrupting XBP1u interaction with FoxO4 in contractile VSMCs or ApoE −/− aorta mimicked XBP1 deficiency-induced VSMC phenotypic switching and aneurysm formation, highlighting the importance of XBP1u-FoxO4-myocardin interactions in maintaining VSMC homeostasis. The XBP1 −/− mice recapitulated the phenotype of myocardin −/− mice, which die at E10.5 because of a lack of VSMC differentiation. 39 In addition, the enhanced inflammatory response of XBP1
SMKO
ApoE
−/− mice in response to AngII infusion is also in line with a previous report that myocardin negatively regulates VSMC inflammatory activation. 56 Our data are also in line with a previous study showing that FoxO4 promotes SMC dedifferentiation in an animal model of restenosis. 41 Of interest, a recent study of aging revealed that FoxO4 protects senescent cell viability by maintaining p53 sequestration in nuclear bodies, and disrupting this interaction restores p53's apoptotic role, highlighting the importance of manipulation of FoxO4 nuclear-cytoplasm shuttling in the regulation of cell functions. 57 Of note, XBP1s and XBP1u share the same N terminus, which is required for FoxO4 binding. 24 Therefore, XBP1s may also interact with FoxO4. Herein, we observed that XBP1u mainly localized in cytoplasm, whereas FoxO4 shuttled between nuclear and cytoplasm on VSMCs phenotypic transition. We observed enhanced association in the contractile phenotype but decreased interaction on dedifferentiation between XBP1u and FoxO4 in the cytoplasm of VSMCs. Interrupting XBP1u and FoxO4 cytoplasmic interaction in contractile VSMCs accelerates the nuclear interaction between FoxO4 and myocardin and causes cellular dedifferentiation. In contrast to XBP1u, XBP1s predominately localized in the nucleus. Although we did observe XBP1s-FoxO4 interaction in dedifferentiated SMCs (Online Figure VIID) , we did not find XBP1s-FoxO4 association in contractile VSMCs ( Figure 5C ). In accordance, XBP1s did not interfere with the interaction between FoxO4 and myocardin and did not affect the inhibition of FoxO4 on myocardin-induced transactivation. In addition, consistent with other studies, we found that inhibition of XBP1 splicing leads to enhanced SMC markers expression, 22 suggesting opposite effect of XBP1u and XBP1s on regulation of VSMCs phenotypic transition. XBP1u, but not XBP1s, association with FoxO4 is pivotal for maintaining VSMC contractile phenotype and homeostasis. In addition to VSMC phenotypic switching, the aggravation of vascular inflammation and extracellular matrix degradation in aneurysmal XBP1 SMKO mice may involve the direct activation of MMP-9 transcription by FoxO4 during XBP1 deficiency. Targeting XBP1u-FoxO4 interactions may provide a novel strategy for the prevention of aneurysm-related disease.
